RxDoctor Payments Data

Niraj Desai, MD

Nephrology · Macon, GANPI 1063679769

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $3,000 of the $3,906 with a category attached, or 76.8%. Calliditas Therapeutics US Inc. accounts for 89.3% of it on its own, with 9 other manufacturers making up the rest. 2024 is the largest year on record at $3,535, more than ten times the $115 reported in 2021.

$3,906in general payments, 2019–2025

Across 22 payments — averaging $177.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Calliditas Therapeutics US Inc.$3K
  • AstraZeneca$94
  • Vifor Pharma, Inc.$74
  • Renalytix AI, Inc.$60
  • Aurinia Pharma U.S., Inc.$55
  • Amgen$44
  • plus $92 from 4 others
$124,910in research payments, 2019–2025

Across 4 payments — averaging $31,227 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Vertex$125K

What the payments were for

  • Consulting fees$3,00077%
  • Travel & lodging$47912%
  • Food & beverage$40610%
  • Education$211%

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,906 in reported general payments places this provider in the 70th percentile of 388 nephrology providers in Georgia.

See all nephrology providers in Georgia

Medicare billing

Part B allowed, 2024
$5,126
Medicare patients
23
Services billed
40

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol17$25,584
Prednisolone Acetate29$1,355
Lisinopril13$59
Chlorthalidone11$39
Amlodipine Besylate14$30

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$94$25,58417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 388 nephrology providers in Georgia.

Other nephrology in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →